Evolus (NASDAQ:EOLS) Insider Rui Avelar Sells 29,996 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 29,996 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $146,680.44. Following the sale, the insider directly owned 430,542 shares of the company’s stock, valued at $2,105,350.38. This represents a 6.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Rui Avelar also recently made the following trade(s):

• On Monday, December 22nd, Rui Avelar sold 2,261 shares of Evolus stock. The shares were sold at an average price of $7.15, for a total value of $16,166.15.

Evolus Stock Performance

Shares of NASDAQ EOLS traded down $0.08 during trading on Thursday, reaching $4.76. The stock had a trading volume of 26,137 shares, compared to its average volume of 1,354,300. The firm’s 50 day moving average price is $4.83 and its two-hundred day moving average price is $6.08. Evolus, Inc. has a one year low of $4.09 and a one year high of $13.66. The stock has a market cap of $309.36 million, a PE ratio of -5.86 and a beta of 1.02.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The company had revenue of $90.30 million during the quarter, compared to analyst estimates of $89.58 million. On average, research analysts expect that Evolus, Inc. will post -0.61 earnings per share for the current year.

Analysts Set New Price Targets

EOLS has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. HC Wainwright dropped their target price on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. BTIG Research reaffirmed a “buy” rating and issued a $13.00 price target on shares of Evolus in a research note on Wednesday, March 4th. Finally, Mizuho set a $15.00 price objective on Evolus in a research note on Wednesday, February 4th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Institutional Trading of Evolus

Several hedge funds have recently bought and sold shares of the stock. Manchester Capital Management LLC bought a new stake in shares of Evolus in the second quarter worth about $26,000. State of Alaska Department of Revenue purchased a new stake in Evolus during the third quarter valued at $26,000. Larson Financial Group LLC lifted its position in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Evolus during the 4th quarter valued at about $34,000. Finally, Wexford Capital LP bought a new position in shares of Evolus during the 3rd quarter valued at approximately $37,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.